首页> 外国专利> Molecular flux rates through critical pathways measured by stable isotope labeling in vivo, as biomarkers of drug action and disease activity

Molecular flux rates through critical pathways measured by stable isotope labeling in vivo, as biomarkers of drug action and disease activity

机译:体内通过稳定同位素标记测量的通过关键途径的分子通量率,作为药物作用和疾病活动的生物标志物

摘要

The methods described herein enable the evaluation of compounds on subjects to assess their therapeutic efficacy or toxic effects. The target of analysis is the underlying biochemical process or processes (i.e., metabolic process) thought to be involved in disease pathogenesis. Molecular flux rates within the one or more biochemical processes serve as biomarkers and are quantitated and compared with the molecular flux rates (i.e., biomarker) from control subjects (i.e., subjects not exposed to the compounds). Any change in the biomarker in the subject relative to the biomarker in the control subject provides the necessary information to evaluate therapeutic efficacy of an administered drug or a toxic effect and to develop the compound further if desired.
机译:本文所述的方法使得能够对受试者进行化合物的评估以评估其治疗功效或毒性作用。分析的目标是被认为与疾病发病机制有关的潜在生化过程或过程(即代谢过程)。一种或多种生化过程中的分子通量率用作生物标志物,并进行定量,并与对照受试者(即未暴露于化合物的受试者)的分子通量率(即生物标志物)进行比较。受试者中生物标志物相对于对照受试者中生物标志物的任何变化都提供了必要的信息,以评估所施用药物的治疗功效或毒性作用,并在需要时进一步开发该化合物。

著录项

  • 公开/公告号US9720002B2

    专利类型

  • 公开/公告日2017-08-01

    原文格式PDF

  • 申请/专利权人 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA;

    申请/专利号US201414201759

  • 发明设计人 MARC K. HELLERSTEIN;

    申请日2014-03-07

  • 分类号G06F19/10;G01N33/68;G01N33/50;G01N33/60;G01N33/92;G01N33/58;

  • 国家 US

  • 入库时间 2022-08-21 13:43:57

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号